Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

National Trends in Utilization and 1-Year Outcomes with Transplantation of HCV-Viremic Kidneys.

Potluri VS, Goldberg DS, Mohan S, Bloom RD, Sawinski D, Abt PL, Blumberg EA, Parikh CR, Sharpe J, Reddy KR, Molnar MZ, Sise M, Reese PP.

J Am Soc Nephrol. 2019 Sep 12. pii: ASN.2019050462. doi: 10.1681/ASN.2019050462. [Epub ahead of print]

PMID:
31515244
2.

Peri-transplant eculizumab does not prevent delayed graft function in deceased donor kidney transplant recipients: results of two randomized controlled pilot trials.

Schröppel B, Akalin E, Baweja M, Bloom RD, Florman S, Goldstein M, Haydel B, Hricik DE, Kulkarni S, Levine M, Mehrotra A, Patel A, Poggio ED, Ratner L, Shapiro R, Heeger PS.

Am J Transplant. 2019 Aug 26. doi: 10.1111/ajt.15580. [Epub ahead of print]

PMID:
31452319
3.

In Their Own Words: Experiences of Caregivers of Adults With Cancer as Expressed on Social Media.

Bloom RD, Beck S, Chou WS, Reblin M, Ellington L.

Oncol Nurs Forum. 2019 Sep 1;46(5):617-630. doi: 10.1188/19.ONF.617-630.

PMID:
31424447
4.

The effect of transfer to adult transplant care on kidney function and immunosuppressant drug level variability in pediatric kidney transplant recipients.

Fernandez HE, Amaral S, Shaw PA, Doyle AM, Bloom RD, Palmer JA, Baluarte HJ, Furth SL.

Pediatr Transplant. 2019 Sep;23(6):e13527. doi: 10.1111/petr.13527. Epub 2019 Jun 17.

PMID:
31209988
5.

Early emergence of anti-HCV antibody implicates donor origin in recipients of an HCV-infected organ.

Porrett PM, Reese PP, Holzmayer V, Coller KE, Kuhns M, Van Deerlin VM, Gentile C, Smith JR, Sicilia A, Woodards A, McLean R, Abt P, Bloom RD, Reddy KR, Blumberg E, Cloherty G, Goldberg D.

Am J Transplant. 2019 Sep;19(9):2525-2532. doi: 10.1111/ajt.15415. Epub 2019 May 28.

PMID:
31066215
6.

Single-center, real-world experience with granulocyte colony-stimulating factor for management of leukopenia following kidney transplantation.

Hamel S, Kuo V, Sawinski D, Johnson D, Bloom RD, Bleicher M, Goral S, Lim MA, Trofe-Clark J.

Clin Transplant. 2019 Jun;33(6):e13541. doi: 10.1111/ctr.13541. Epub 2019 Apr 11.

PMID:
30887581
7.

Using (cell-free) DNA to incriminate rejection as the cause of kidney allograft dysfunction: Do we have a verdict?

Bloom RD.

Am J Transplant. 2019 Jun;19(6):1609-1610. doi: 10.1111/ajt.15338. Epub 2019 Mar 26. No abstract available.

PMID:
30835968
8.

Introduction to hepatitis C virus infection in patients with kidney disease: A roadmap for nephrologists.

Bloom RD, Roth D.

Semin Dial. 2019 Mar;32(2):91-92. doi: 10.1111/sdi.12775. No abstract available.

PMID:
30827039
9.

Characterization of early hepatic injury in HCV-negative recipients of HCV-infected kidneys.

Mazur RD, Abt PL, Blumberg EA, Bloom RD, Reddy KR, Reese PP, Goldberg DS.

Clin Transplant. 2019 Apr;33(4):e13494. doi: 10.1111/ctr.13494. Epub 2019 Mar 6. No abstract available.

PMID:
30779252
10.

Transplanting hepatitis C virus-infected hearts into uninfected recipients: A single-arm trial.

McLean RC, Reese PP, Acker M, Atluri P, Bermudez C, Goldberg LR, Abt PL, Blumberg EA, Van Deerlin VM, Reddy KR, Bloom RD, Hasz R, Suplee L, Sicilia A, Woodards A, Zahid MN, Bar KJ, Porrett P, Levine MH, Hornsby N, Gentile C, Smith J, Goldberg DS.

Am J Transplant. 2019 Sep;19(9):2533-2542. doi: 10.1111/ajt.15311. Epub 2019 Mar 20.

PMID:
30768838
11.

Mortality and Kidney Transplantation Outcomes Among Hepatitis C Virus-Seropositive Maintenance Dialysis Patients: A Retrospective Cohort Study.

Sawinski D, Forde KA, Lo Re V 3rd, Goldberg DS, Cohen JB, Locke JE, Bloom RD, Brensinger C, Weldon J, Shults J, Reese PP.

Am J Kidney Dis. 2019 Jun;73(6):815-826. doi: 10.1053/j.ajkd.2018.11.009. Epub 2019 Jan 29.

PMID:
30704882
12.

Management and treatment of the HCV-infected kidney transplant patient.

Wong T, Bloom RD.

Semin Dial. 2019 Mar;32(2):169-178. doi: 10.1111/sdi.12766. Epub 2018 Dec 9. Review.

PMID:
30536995
13.

Twelve-Month Outcomes After Transplant of Hepatitis C-Infected Kidneys Into Uninfected Recipients: A Single-Group Trial.

Reese PP, Abt PL, Blumberg EA, Van Deerlin VM, Bloom RD, Potluri VS, Levine M, Porrett P, Sawinski D, Nazarian SM, Naji A, Hasz R, Suplee L, Trofe-Clark J, Sicilia A, McCauley M, Gentile C, Smith J, Niknam BA, Bleicher M, Reddy KR, Goldberg DS.

Ann Intern Med. 2018 Sep 4;169(5):273-281. doi: 10.7326/M18-0749. Epub 2018 Aug 7.

PMID:
30083748
14.
15.

A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits.

Gumber R, Cohen JB, Palmer MB, Kobrin SM, Vogl DT, Wasserstein AG, Nasta SD, Bleicher MB, Bloom RD, Dember L, Cohen A, Weiss BM, Hogan JJ.

Kidney Int. 2018 Jul;94(1):199-205. doi: 10.1016/j.kint.2018.02.020. Epub 2018 May 11.

PMID:
29759418
16.

The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes.

Axelrod DA, Schnitzler MA, Alhamad T, Gordon F, Bloom RD, Hess GP, Xiao H, Nazzal M, Segev DL, Dharnidharka VR, Naik AS, Lam NN, Ouseph R, Kasiske BL, Durand CM, Lentine KL.

Am J Transplant. 2018 Oct;18(10):2473-2482. doi: 10.1111/ajt.14895. Epub 2018 May 29.

PMID:
29701909
17.

Safety and Feasibility of Outpatient Rabbit Antithymocyte Globulin Induction Therapy Administration in Kidney Transplant Recipients.

Varga AN, Johnson D, Sawinski DL, Lim MA, Bloom RD, Abt PL, Goral S, Bleicher M, Levine MH, Naji A, Nazarian S, Porrett P, Trofe-Clark J.

Pharmacotherapy. 2018 Jun;38(6):620-627. doi: 10.1002/phar.2116.

PMID:
29665038
18.

The changing face of adult posttransplant lymphoproliferative disorder: Changes in histology between 1999 and 2013.

Tsai DE, Bagley S, Reshef R, Shaked A, Bloom RD, Ahya V, Goldberg L, Chung A, Debonera F, Schuster SJ, Huntington SF.

Am J Hematol. 2018 Jul;93(7):874-881. doi: 10.1002/ajh.25116. Epub 2018 May 6.

19.

Impact of prolonged dialysis prior to renal transplantation.

Aufhauser DD Jr, Peng AW, Murken DR, Concors SJ, Abt PL, Sawinski D, Bloom RD, Reese PP, Levine MH.

Clin Transplant. 2018 Jun;32(6):e13260. doi: 10.1111/ctr.13260. Epub 2018 Jun 25.

20.

Hepatitis E Virus Infection in Kidney Transplant Patients: A Single-Center Study.

Lim MA, Kamili S, Cohen JB, Green-Montfort T, Tejada-Strop A, Kohli J, Drobeniuc J, Patel P, Vanderveen M, Bloom RD.

Transplantation. 2018 Apr;102(4):e126-e127. doi: 10.1097/TP.0000000000002071. No abstract available.

PMID:
29329183
21.

Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients.

Trofe-Clark J, Brennan DC, West-Thielke P, Milone MC, Lim MA, Neubauer R, Nigro V, Bloom RD.

Am J Kidney Dis. 2018 Mar;71(3):315-326. doi: 10.1053/j.ajkd.2017.07.018. Epub 2017 Nov 20.

22.

Recurrent glomerular disease after kidney transplantation.

Blosser CD, Bloom RD.

Curr Opin Nephrol Hypertens. 2017 Nov;26(6):501-508. doi: 10.1097/MNH.0000000000000358. Review.

PMID:
28832357
23.

The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation.

Levitsky J, Formica RN, Bloom RD, Charlton M, Curry M, Friedewald J, Friedman J, Goldberg D, Hall S, Ison M, Kaiser T, Klassen D, Klintmalm G, Kobashigawa J, Liapakis A, O'Conner K, Reese P, Stewart D, Terrault N, Theodoropoulos N, Trotter J, Verna E, Volk M.

Am J Transplant. 2017 Nov;17(11):2790-2802. doi: 10.1111/ajt.14381. Epub 2017 Jul 1.

24.

Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients.

Goldberg DS, Abt PL, Blumberg EA, Van Deerlin VM, Levine M, Reddy KR, Bloom RD, Nazarian SM, Sawinski D, Porrett P, Naji A, Hasz R, Suplee L, Trofe-Clark J, Sicilia A, McCauley M, Farooqi M, Gentile C, Smith J, Reese PP.

N Engl J Med. 2017 Jun 15;376(24):2394-2395. doi: 10.1056/NEJMc1705221. Epub 2017 Apr 30. No abstract available.

PMID:
28459186
25.

Immunosuppression for kidney transplantation: Where are we now and where are we going?

Lim MA, Kohli J, Bloom RD.

Transplant Rev (Orlando). 2017 Jan;31(1):10-17. doi: 10.1016/j.trre.2016.10.006. Epub 2016 Oct 11. Review.

PMID:
28340885
26.

Comparing Outcomes between Antibody Induction Therapies in Kidney Transplantation.

Koyawala N, Silber JH, Rosenbaum PR, Wang W, Hill AS, Reiter JG, Niknam BA, Even-Shoshan O, Bloom RD, Sawinski D, Nazarian S, Trofe-Clark J, Lim MA, Schold JD, Reese PP.

J Am Soc Nephrol. 2017 Jul;28(7):2188-2200. doi: 10.1681/ASN.2016070768. Epub 2017 Mar 20.

27.

Histopathologic changes in anti-angiotensin II type 1 receptor antibody-positive kidney transplant recipients with acute rejection and no donor specific HLA antibodies.

Lim MA, Palmer M, Trofe-Clark J, Bloom RD, Jackson A, Philogene MC, Kamoun M.

Hum Immunol. 2017 Apr;78(4):350-356. doi: 10.1016/j.humimm.2017.03.004. Epub 2017 Mar 8.

PMID:
28284829
28.

Cell-Free DNA and Active Rejection in Kidney Allografts.

Bloom RD, Bromberg JS, Poggio ED, Bunnapradist S, Langone AJ, Sood P, Matas AJ, Mehta S, Mannon RB, Sharfuddin A, Fischbach B, Narayanan M, Jordan SC, Cohen D, Weir MR, Hiller D, Prasad P, Woodward RN, Grskovic M, Sninsky JJ, Yee JP, Brennan DC; Circulating Donor-Derived Cell-Free DNA in Blood for Diagnosing Active Rejection in Kidney Transplant Recipients (DART) Study Investigators.

J Am Soc Nephrol. 2017 Jul;28(7):2221-2232. doi: 10.1681/ASN.2016091034. Epub 2017 Mar 9.

29.

Development of proteinuria and focal segmental glomerulosclerosis during direct-acting antiviral therapy for hepatitis C virus infection.

Hogan JJ, Lim MA, Palmer MB, Bloom RD, Chung RT, Sise ME.

Hepatology. 2017 Aug;66(2):658-660. doi: 10.1002/hep.29125. Epub 2017 Jun 22. No abstract available.

PMID:
28211090
30.

Automated Reminders and Physician Notification to Promote Immunosuppression Adherence Among Kidney Transplant Recipients: A Randomized Trial.

Reese PP, Bloom RD, Trofe-Clark J, Mussell A, Leidy D, Levsky S, Zhu J, Yang L, Wang W, Troxel A, Feldman HI, Volpp K.

Am J Kidney Dis. 2017 Mar;69(3):400-409. doi: 10.1053/j.ajkd.2016.10.017. Epub 2016 Dec 7.

PMID:
27940063
31.

Kidney Transplantation From a Donor With Sickle Cell Disease.

Rossidis A, Lim MA, Palmer M, Levine MH, Naji A, Bloom RD, Abt PL.

Am J Transplant. 2017 Feb;17(2):569-571. doi: 10.1111/ajt.14063. Epub 2016 Oct 21.

32.

Long-term patient survival and kidney allograft survival in post-transplant diabetes mellitus: a single-center retrospective study.

Dienemann T, Fujii N, Li Y, Govani S, Kosaraju N, Bloom RD, Feldman HI.

Transpl Int. 2016 Sep;29(9):1017-28. doi: 10.1111/tri.12807. Epub 2016 Jul 7.

33.

Measures of Global Health Status on Dialysis Signal Early Rehospitalization Risk after Kidney Transplantation.

Harhay MN, Hill AS, Wang W, Even-Shoshan O, Mussell AS, Bloom RD, Feldman HI, Karlawish JH, Silber JH, Reese PP.

PLoS One. 2016 Jun 3;11(6):e0156532. doi: 10.1371/journal.pone.0156532. eCollection 2016.

34.

A Paired Kidney Analysis of Multiorgan Transplantation: Implications for Allograft Survival.

Choudhury RA, Reese PP, Goldberg DS, Bloom RD, Sawinski DL, Abt PL.

Transplantation. 2017 Feb;101(2):368-376. doi: 10.1097/TP.0000000000001151.

PMID:
26982953
35.

Successful Treatment of Hepatitis C in Renal Transplant Recipients With Direct-Acting Antiviral Agents.

Sawinski D, Kaur N, Ajeti A, Trofe-Clark J, Lim M, Bleicher M, Goral S, Forde KA, Bloom RD.

Am J Transplant. 2016 May;16(5):1588-95. doi: 10.1111/ajt.13620. Epub 2016 Feb 5.

36.

National outcomes of kidney transplantation from deceased diabetic donors.

Cohen JB, Bloom RD, Reese PP, Porrett PM, Forde KA, Sawinski DL.

Kidney Int. 2015 Oct 21. doi: 10.1038/ki.2015.325. [Epub ahead of print]

37.

Novel Hepatitis C Treatment and the Impact on Kidney Transplantation.

Sawinski D, Bloom RD.

Transplantation. 2015 Dec;99(12):2458-66. doi: 10.1097/TP.0000000000000847. Review.

PMID:
26214816
38.

Functional status, time to transplantation, and survival benefit of kidney transplantation among wait-listed candidates.

Reese PP, Shults J, Bloom RD, Mussell A, Harhay MN, Abt P, Levine M, Johansen KL, Karlawish JT, Feldman HI.

Am J Kidney Dis. 2015 Nov;66(5):837-45. doi: 10.1053/j.ajkd.2015.05.015. Epub 2015 Jul 7.

39.

Beyond the NIH Multicenter HIV Transplant Trial Experience: Outcomes of HIV+ Liver Transplant Recipients Compared to HCV+ or HIV+/HCV+ Coinfected Recipients in the United States.

Sawinski D, Goldberg DS, Blumberg E, Abt PL, Bloom RD, Forde KA.

Clin Infect Dis. 2015 Oct 1;61(7):1054-62. doi: 10.1093/cid/civ471. Epub 2015 Jun 16.

40.

An Assessment of HIV-Infected Patients Dying in Care for Deceased Organ Donation in a United States Urban Center.

Richterman A, Sawinski D, Reese PP, Lee DH, Clauss H, Hasz RD, Thomasson A, Goldberg DS, Abt PL, Forde KA, Bloom RD, Doll SL, Brady KA, Blumberg EA.

Am J Transplant. 2015 Aug;15(8):2105-16. doi: 10.1111/ajt.13308. Epub 2015 May 14.

41.

Response to: lower-dose valganciclovir for prevention of cytomegalovirus after solid organ transplant: an important tradeoff.

Stevens DR, Sawinski D, Blumberg E, Bloom RD, Trofe-Clark J.

Transpl Infect Dis. 2015 Aug;17(4):625-6. doi: 10.1111/tid.12396. Epub 2015 Jun 26. No abstract available.

PMID:
25919221
42.

AST/ASTS workshop on increasing organ donation in the United States: creating an "arc of change" from removing disincentives to testing incentives.

Salomon DR, Langnas AN, Reed AI, Bloom RD, Magee JC, Gaston RS; AST/ASTS Incentives Workshop Group (IWG).

Am J Transplant. 2015 May;15(5):1173-9. doi: 10.1111/ajt.13233. Epub 2015 Mar 31.

43.

Superior outcomes in HIV-positive kidney transplant patients compared with HCV-infected or HIV/HCV-coinfected recipients.

Sawinski D, Forde KA, Eddinger K, Troxel AB, Blumberg E, Tebas P, Abt PL, Bloom RD.

Kidney Int. 2015 Aug;88(2):341-9. doi: 10.1038/ki.2015.74. Epub 2015 Mar 25.

44.

Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management.

Huprikar S, Danziger-Isakov L, Ahn J, Naugler S, Blumberg E, Avery RK, Koval C, Lease ED, Pillai A, Doucette KE, Levitsky J, Morris MI, Lu K, McDermott JK, Mone T, Orlowski JP, Dadhania DM, Abbott K, Horslen S, Laskin BL, Mougdil A, Venkat VL, Korenblat K, Kumar V, Grossi P, Bloom RD, Brown K, Kotton CN, Kumar D.

Am J Transplant. 2015 May;15(5):1162-72. doi: 10.1111/ajt.13187. Epub 2015 Feb 23.

45.

Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.

Stevens DR, Sawinski D, Blumberg E, Galanakis N, Bloom RD, Trofe-Clark J.

Transpl Infect Dis. 2015 Apr;17(2):163-73. doi: 10.1111/tid.12349. Epub 2015 Feb 6.

PMID:
25661673
46.

Transplant nephrectomy: histologic findings—a single center study.

Goral S, Brukamp K, Ticehurst EH, Abt PL, Bloom RD, Kearns J, Constantinescu S, Kamoun M, Tomaszewski J.

Am J Nephrol. 2014;40(5):491-8. doi: 10.1159/000369865. Epub 2014 Dec 9.

PMID:
25504182
47.

Kidney transplant outcomes for prior living organ donors.

Potluri V, Harhay MN, Wilson FP, Bloom RD, Reese PP.

J Am Soc Nephrol. 2015 May;26(5):1188-94. doi: 10.1681/ASN.2014030302. Epub 2014 Nov 20.

48.

Selecting appropriate controls for kidney donors--reply.

Reese PP, Bloom RD, Feldman HI, Garg AX, Mussell A, Shults J, Silber JH.

Am J Transplant. 2015 Jan;15(1):287-8. doi: 10.1111/ajt.13015. Epub 2014 Oct 31. No abstract available.

49.

Current status of kidney transplantation in HIV-infected patients.

Sawinski D, Bloom RD.

Curr Opin Nephrol Hypertens. 2014 Nov;23(6):619-24. doi: 10.1097/MNH.0000000000000071. Review.

PMID:
25295961
50.

Persistent BK viremia does not increase intermediate-term graft loss but is associated with de novo donor-specific antibodies.

Sawinski D, Forde KA, Trofe-Clark J, Patel P, Olivera B, Goral S, Bloom RD.

J Am Soc Nephrol. 2015 Apr;26(4):966-75. doi: 10.1681/ASN.2014010119. Epub 2014 Sep 25.

Supplemental Content

Loading ...
Support Center